🌅 Pre-Market Pulse

S&P Futures 7,399.50 ▲ +13.25 (+0.18%)	Nasdaq Futures 29,120.50 ▲ +62.00 (+0.21%)	Dow Futures 49,277.00 ▲ +83.00 (+0.17%)
10Y Treasury 4.59% ▲ +0.13%	US Dollar 99.22 ▼ -0.10 (-0.11%)	Bitcoin $76,658 ▼ -$750 (-0.97%)

Good morning! It is Monday, May 18, and futures are nudging higher across the board even as Treasury yields push to levels that tend to make equity investors a little fidgety. The headliner this morning is a brutal pre-market drop in Regeneron after a key cancer trial came up short. Here is everything you need to know before the open.

👀 What to Watch Today

Today's session is relatively light on scheduled economic data, which means the market will be leaning heavily on company-specific news to find direction. That puts a spotlight on pharma names, where both Merck and Regeneron are commanding attention for very different reasons.

On the macro side, keep an eye on how the bond market behaves as the session develops. The 10-year yield is sitting at 4.59% and the 30-year is above 5.13%, both up noticeably overnight. If yields continue climbing through the morning, growth stocks and rate-sensitive sectors like utilities and real estate could feel the pressure.

The dollar index at 99.22 is slightly softer, which tends to be a mild tailwind for multinational earnings and commodities. Watch how energy names respond given the ongoing India-Russia oil story, and keep clean energy ETFs like TAN, ICLN, and QCLN on your screen after China's solar export surge hit the tape.

What’s next for Tesla? [ad]

🌏 Overnight Recap

Overseas markets were a mixed bag heading into Monday's open. European indices dealt with fresh M&A drama after Commerzbank officially rejected UniCredit's takeover bid, extending one of the more drawn-out cross-border banking sagas in recent European corporate history. CRZBF and CRZBY will be names to track as analysts weigh what comes next for both institutions.

In Asia, trade-related data continued to command attention. China's April solar export figures came in with a stunning 60% year-over-year jump, a number that landed despite the Chinese government pulling back some domestic subsidies. That data is already moving clean energy ETFs in pre-market and could ripple through the broader renewable sector today.

Bitcoin slipped nearly 1% overnight to around 76,658, a modest pullback that is not setting off alarms but is worth noting for anyone with crypto exposure. The slight DXY softness did not provide the lift crypto traders might have hoped for, suggesting some independent selling pressure in digital assets heading into the week.

Forget oil — this changes everything about American energy... [ad]

📊 Pre-Market Movers

The biggest pre-market story by a wide margin is Regeneron, with REGN dropping roughly 11.8% after the company disclosed that its experimental melanoma treatment failed to hit the primary endpoint in a late-stage trial. That is a significant miss for a drug that carried meaningful expectations, and it will likely weigh on the broader biotech space when the opening bell rings.

On the brighter side, Merck is getting a lift after announcing its endometrial cancer drug cleared its primary objectives in a late-stage trial. MRK had already been in focus this year, and positive Phase 3 data gives the stock a near-term catalyst that could attract buyers. AstraZeneca is also in the green after U.S. regulators approved its hypertension drug baxdrostat, opening a major commercial opportunity for the company in one of the largest therapeutic categories in medicine.

Intel is drawing some color after a Fortune magazine interview surfaced in which President Trump suggested he should have pushed for a larger U.S. government stake in INTC. The comments are vague in terms of immediate policy implications, but they are enough to put the stock on watch for any follow-through headlines through the morning session.

Trump Takes Emergency Action - 67 Million Americans at Risk of Blackouts [ad]

🔍 Today's Watchlist

1. REGN: Watch for potential further downside as the melanoma trial miss gets fully digested by the street
2. MRK: Endometrial cancer trial success could attract fresh institutional interest at the open
3. TAN, ICLN, QCLN: China solar export surge may drive unusual volume in clean energy ETFs today
4. 10-Year Treasury at 4.59%: Rising yields could weigh on high-multiple growth names if momentum continues
5. LULU: Chip Wilson founder feud goes public with shareholder letter, governance headlines may spook momentum traders

🎯 The Morning Playbook

The setup heading into Monday is cautiously constructive. Futures are green, the dollar is soft, and there are real company-level catalysts on both sides of the ledger to trade around. The key risk is whether rising Treasury yields become a headwind that caps any upside gains as the session progresses.

For active traders, the pharma space is the clearest area of opportunity today. The REGN selloff could attract bargain hunters by midday, but it could also see continued pressure if analysts begin trimming price targets. MRK and AZN, by contrast, look positioned to outperform the tape on the back of genuine clinical progress.

Zoom out for a moment and the bigger theme is that the market is navigating a world of competing signals: strong corporate news here, rising rates there, geopolitical trade noise in the background. The investors who do best in this environment tend to be the ones focused on fundamentals rather than the daily noise. Stay curious, stay selective, and let the data do the talking.

Trump’s new AI data center “bigger than Texas” [ad]